Recently, Shijiazhuang Yiling Pharmaceutical Co, Ltd. announced that the 
ministry of foreign affairs of the People's Republic of China has purchased 
700,000 boxes of Lianhua Qingwen and distribute them to each Chinese embassy. 
The health packages for Chinese students studying overseas are also equipped 
with Lianhua Qingwen.

Lianhua Qingwen gained the national science and technology recognition to treat 
influenza 

Lianhua Qingwen is an innovative Chinese medicine developed to treat influenza 
during SARS in 2003. After 347 days' research and development, it passed the 
new drug evaluation of the national medical products administration at one 
time, and obtained the new drug certificate and production approval.

Lianhua Qingwen was listed as the recommended drug in China for the COVID-19 
epidemic

In 2020, Lianhua Qingwen Capsules/Granules were listed as the recommended drug 
in the "Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme" (Trial 
version IV/V/VI/VII) which was jointly issued by the National Health Commission 
and the State Administration of Traditional Medicine of China. It has become 
the most frequently recommended proprietary Chinese medicine in the treatment 
of COVID-19. More than 20 provinces and cities in China including Hubei, 
Guangzhou, Zhejiang, Shandong and Hebei recommended Lianhua Qingwen capsules 
(granules). Hubei and Heilongjiang province as well as many other provinces 
have listed Lianhua Qingwen capsules/granules as reserved medicine.The ministry 
of industry and information technology of the state has taken them as the 
medical emergency guarantee in the list of key guarantee materials.  

Lianhua Qingwen has been exported to many countries and regions

As a representative of modern Chinese medicine, Lianhua Qingwen capsules have 
been gradually recognized at home and abroad for its inhibitory and alleviating 
effects on COVID-19. Recently, Lianhua Qingwen capsule has received the 
approval of the modern herbal medicine registration issued by the ministry of 
health of Thailand. In addition to Thailand, Lianhua Qingwen capsules have been 
registered in Hong Kong (SAR of China), Macao (SAR of China), Brazil, 
Indonesia, Canada, Mozambique, Romania and other places as "Chinese patent 
medicine", "medicine", "plant medicine" and "natural health products", and have 
been approved for marketing.

SOURCE  Shijiazhuang Yiling Pharmaceutical Co, Ltd.